Prenetics Approves Major Share Capital Increase at August 2025 Meeting

Prenetics Group ( (PRE) ) has shared an announcement.

On August 1, 2025, Prenetics Global Limited held an Extraordinary General Meeting of Shareholders, where they approved an increase in the company’s authorized share capital from US$50,000 to US$320,000. This decision, supported by a significant majority of shareholders, is expected to provide the company with greater flexibility for future capital raising activities, particularly in support of its Bitcoin treasury strategy and general corporate purposes. The move is anticipated to enhance Prenetics’ strategic opportunities and long-term shareholder value.

The most recent analyst rating on (PRE) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Prenetics Group stock, see the PRE Stock Forecast page.

Spark’s Take on PRE Stock

According to Spark, TipRanks’ AI Analyst, PRE is a Neutral.

The overall score of 54 reflects financial challenges despite a stable balance sheet and positive technical indicators. While the stock shows upward momentum, persistent profitability and cash flow issues, along with a negative P/E ratio, highlight the need for cautious optimism. The absence of earnings call insights or corporate events leaves financial performance as the dominant factor.

To see Spark’s full report on PRE stock, click here.

More about Prenetics Group

Prenetics Global Limited operates in the biotechnology industry, focusing on genetic testing and digital health solutions. The company is known for its innovative health technology products and services, which aim to empower individuals with actionable health insights.

Average Trading Volume: 55,513

Technical Sentiment Signal: Buy

Current Market Cap: $105.2M

Learn more about PRE stock on TipRanks’ Stock Analysis page.